SMRTnet predicts small molecules that bind RNA
The January 2026 Nature Biotechnology abstract reports 40 small-molecule hits across ten disease-associated RNA targets, with nanomolar-to-micromolar binding. One predicted compound reduced MYC expression, inhibited proliferation and promoted apoptosis in three cancer cell lines. SMRTnet combines language models with convolutional and graph attention networks, using RNA secondary structure. These are laboratory results.
Technology: SMRTnet (language-model-based)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: RNA-binding assays and cancer-cell experiments.
- Still unknown: Not assessed: full-paper validation rates and therapeutic performance.
- AI role: Multimodal deep learning predicted small molecule-RNA interactions.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41482542/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.